FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma
Abstract Background The role of FDG-PET/CT imaging in assessing response to immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) is unknown. This study compared complete metabolic response (CMR) rates by FDG-PET and RECIST1.1 via CT or MRI in patients on cemiplimab for > 10 months....
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-10-01
|
| Series: | Cancer Imaging |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40644-021-00426-2 |
| _version_ | 1818884110278459392 |
|---|---|
| author | Luke S. McLean Karda Cavanagh Rodney J. Hicks Jason Callahan Jing Xie Anthony Cardin Annette M. Lim Danny Rischin |
| author_facet | Luke S. McLean Karda Cavanagh Rodney J. Hicks Jason Callahan Jing Xie Anthony Cardin Annette M. Lim Danny Rischin |
| author_sort | Luke S. McLean |
| collection | DOAJ |
| description | Abstract Background The role of FDG-PET/CT imaging in assessing response to immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) is unknown. This study compared complete metabolic response (CMR) rates by FDG-PET and RECIST1.1 via CT or MRI in patients on cemiplimab for > 10 months. Methods This was a single-centre retrospective study of 15 patients treated with cemiplimab for advanced CSCC who had CT/MRI and FDG-PET/CT at > 10 months to assess metabolic treatment response. The median age was 73 years (range 55–84) and 93% were male. RECIST1.1 and PERCIST1.0 tumor responses were evaluated by blinded readers. Results Seventy-three percent (11/15) (95%CI 44.9, 92.2%) achieved a CMR on PET. Of these 11, on RECIST1.1 there was one complete response, 9 partial responses and one stable disease. Conclusions In patients on cemiplimab for > 10 months, there was discordance between CR rates on FDG-PET versus RECIST1.1. FDG-PET/CT may have utility for clarifying depth of response in patients treated with immunotherapy for CSCC. |
| first_indexed | 2024-12-19T15:44:20Z |
| format | Article |
| id | doaj.art-775096a9e5be429ca0c1a19c0432e1b4 |
| institution | Directory Open Access Journal |
| issn | 1470-7330 |
| language | English |
| last_indexed | 2024-12-19T15:44:20Z |
| publishDate | 2021-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Imaging |
| spelling | doaj.art-775096a9e5be429ca0c1a19c0432e1b42022-12-21T20:15:23ZengBMCCancer Imaging1470-73302021-10-012111610.1186/s40644-021-00426-2FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinomaLuke S. McLean0Karda Cavanagh1Rodney J. Hicks2Jason Callahan3Jing Xie4Anthony Cardin5Annette M. Lim6Danny Rischin7Department of Medical Oncology, Peter MacCallum Cancer CentreCancer Imaging, Peter MacCallum Cancer CentreCancer Imaging, Peter MacCallum Cancer CentreCancer Imaging, Peter MacCallum Cancer CentreBiostatistics and Clinical Trials, Peter MacCallum Cancer CentreCancer Imaging, Peter MacCallum Cancer CentreDepartment of Medical Oncology, Peter MacCallum Cancer CentreDepartment of Medical Oncology, Peter MacCallum Cancer CentreAbstract Background The role of FDG-PET/CT imaging in assessing response to immunotherapy in advanced cutaneous squamous cell carcinoma (CSCC) is unknown. This study compared complete metabolic response (CMR) rates by FDG-PET and RECIST1.1 via CT or MRI in patients on cemiplimab for > 10 months. Methods This was a single-centre retrospective study of 15 patients treated with cemiplimab for advanced CSCC who had CT/MRI and FDG-PET/CT at > 10 months to assess metabolic treatment response. The median age was 73 years (range 55–84) and 93% were male. RECIST1.1 and PERCIST1.0 tumor responses were evaluated by blinded readers. Results Seventy-three percent (11/15) (95%CI 44.9, 92.2%) achieved a CMR on PET. Of these 11, on RECIST1.1 there was one complete response, 9 partial responses and one stable disease. Conclusions In patients on cemiplimab for > 10 months, there was discordance between CR rates on FDG-PET versus RECIST1.1. FDG-PET/CT may have utility for clarifying depth of response in patients treated with immunotherapy for CSCC.https://doi.org/10.1186/s40644-021-00426-2Cutaneous cancerImmunotherapyFDG-PETPERCIST1.0RECIST1.1 |
| spellingShingle | Luke S. McLean Karda Cavanagh Rodney J. Hicks Jason Callahan Jing Xie Anthony Cardin Annette M. Lim Danny Rischin FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma Cancer Imaging Cutaneous cancer Immunotherapy FDG-PET PERCIST1.0 RECIST1.1 |
| title | FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma |
| title_full | FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma |
| title_fullStr | FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma |
| title_full_unstemmed | FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma |
| title_short | FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma |
| title_sort | fdg pet ct imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma |
| topic | Cutaneous cancer Immunotherapy FDG-PET PERCIST1.0 RECIST1.1 |
| url | https://doi.org/10.1186/s40644-021-00426-2 |
| work_keys_str_mv | AT lukesmclean fdgpetctimagingforevaluatingdurableresponsestoimmunecheckpointinhibitorsinpatientswithadvancedcutaneoussquamouscellcarcinoma AT kardacavanagh fdgpetctimagingforevaluatingdurableresponsestoimmunecheckpointinhibitorsinpatientswithadvancedcutaneoussquamouscellcarcinoma AT rodneyjhicks fdgpetctimagingforevaluatingdurableresponsestoimmunecheckpointinhibitorsinpatientswithadvancedcutaneoussquamouscellcarcinoma AT jasoncallahan fdgpetctimagingforevaluatingdurableresponsestoimmunecheckpointinhibitorsinpatientswithadvancedcutaneoussquamouscellcarcinoma AT jingxie fdgpetctimagingforevaluatingdurableresponsestoimmunecheckpointinhibitorsinpatientswithadvancedcutaneoussquamouscellcarcinoma AT anthonycardin fdgpetctimagingforevaluatingdurableresponsestoimmunecheckpointinhibitorsinpatientswithadvancedcutaneoussquamouscellcarcinoma AT annettemlim fdgpetctimagingforevaluatingdurableresponsestoimmunecheckpointinhibitorsinpatientswithadvancedcutaneoussquamouscellcarcinoma AT dannyrischin fdgpetctimagingforevaluatingdurableresponsestoimmunecheckpointinhibitorsinpatientswithadvancedcutaneoussquamouscellcarcinoma |